Alnylam Pharmaceuticals (ALNY) director gets 3,279 stock options grant

Rhea-AI Filing Summary

Alnylam Pharmaceuticals director Stuart A. Arbuckle reported receiving a stock option award for 3,279 shares of the company’s common stock. The option, granted on January 5, 2026, has an exercise price of $397.83 per share and is structured as a right to buy shares in the future.

According to the filing, the option will vest in three equal installments, with one third of the shares vesting on each of the first, second and third anniversaries of the grant date. Following this grant, Arbuckle beneficially owns 3,279 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Arbuckle Stuart A

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	3,279	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 3,279 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Arbuckle Stuart A

(Last) (First) (Middle)

675 WEST KENDALL STREET

HENRI A. TERMEER SQUARE

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ALNYLAM PHARMACEUTICALS, INC. [ ALNY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$397.83	01/05/2026		A		3,279		(1)	01/05/2036	Common Stock	3,279	$0.0	3,279	D

Explanation of Responses:

1. The stock option will vest as to one third of the shares on each of the first, second and third anniversaries of the date of grant.

	By: Brett Budzinski, Attorney-in-Fact For: Stuart A. Arbuckle	01/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ALNY report for Stuart A. Arbuckle?

The filing reports that Stuart A. Arbuckle, a director of Alnylam Pharmaceuticals, Inc., received a stock option grant covering 3,279 shares of common stock.

How many Alnylam (ALNY) shares are covered by the new stock option?

The stock option gives the reporting person the right to purchase 3,279 shares of Alnylam Pharmaceuticals common stock.

What is the exercise price of the new Alnylam (ALNY) stock options?

The stock option has an exercise price of $397.83 per share for the underlying Alnylam common stock.

How do the Alnylam (ALNY) stock options granted to Stuart A. Arbuckle vest?

The option will vest as to one third of the shares on each of the first, second and third anniversaries of the January 5, 2026 grant date.

What is Stuart A. Arbuckle’s relationship to Alnylam (ALNY)?

Stuart A. Arbuckle is listed in the filing as a director of Alnylam Pharmaceuticals, Inc. and is not identified as an officer or 10% owner.

Are the Alnylam (ALNY) options held directly or indirectly by Stuart A. Arbuckle?

The filing shows the 3,279 stock options as directly owned by the reporting person, with no indirect ownership entity specified.